Max Robotics — Global Service Robot Directory + US Certification

About

Thomas Bodin is a leading French urologic oncologist whose research centers on renal cell carcinoma, with a particular focus on optimizing surgical and ablative treatment strategies. His major contributions include landmark comparative studies that help guide clinical decision-making for patients with imperative indications for nephron-sparing therapy. In his pivotal 2016 work (42 citations), Bodin systematically evaluated outcomes of partial nephrectomy versus ablative techniques, providing crucial evidence for tailoring treatment in challenging clinical scenarios. He has been instrumental in shaping national standards of care, serving as a primary author for the French Association of Urology (AFU) Cancer Committee’s successive clinical practice guidelines for kidney cancer management (2016–2022 editions, collectively exceeding 85 citations). These recommendations have become essential references for urologists across France. Bodin also leveraged large-scale national registry data to analyze the impact of robotic-assisted surgery adoption on renal cancer surgical practices, revealing significant shifts in operative trends. His work bridges evidence-based medicine with real-world clinical implementation, making him a key voice in contemporary urologic oncology.